Sugammadex for reversal of moderate-to-deep rocuronium block in a clinical setting: A retrospective report of 10 dogs

Abstract

ObjectiveTo compare recovery times of sugammadex with spontaneous recovery from rocuronium-induced neuromuscular block (NMB) in dogs. Study designRetrospective, unmatchedcase-control study. AnimalsA total of 10 dogs administered sugammadex and 10 dogs recovering spontaneously from rocuronium-induced NMB. MethodsFiles of dogs administered rocuronium between March and August 2023 were inspected. The train-of-four (TOF) count at the time of sugammadex administration and the time between administration and TOF ratio >90% (recovery time) were recorded. The recovery time for those not administered reversal agents was considered from the first TOF value >0 until TOF ratio >90%. The dose of sugammadex and the cumulative dose of rocuronium were recorded. Rocuronium doses and recovery times were compared using Mann–Whitney tests. The coefficient of determination (R2) between the cumulative rocuronium dose and sugammadex dose and the recovery time were calculated. ResultsDogs in the sugammadex and spontaneous recovery groups were administered intravenously (IV) 0.76 (0.4–2.6) and 0.61 (0.3–2.9) mg kg–1 of rocuronium, respectively (p = 0.325). Recovery time after 3.9 (2.9–5.5) mg kg–1 of sugammadex IV was 1 (1–3) minutes and was 20 (10–35) min for spontaneous recovery (p < 0.0001). The R2 for rocuronium and sugammadex doses and recovery times were 0.19 (p = 0.2) and 0.012 (p = 0.758). Conclusions and clinical relevanceSugammadex 2.9–5.5 mg kg–1 reversed moderate (TOF count 1–3) or deep (TOF count 0) rocuronium-induced NMB within 3 minutes, substantially faster than spontaneous recovery.